Daiichi Sankyo Company, Limited has entered into a strategic collaboration with AgonOx, Inc., a privately held biotechnology company, to develop an undisclosed immuno-oncology target.
Under terms of the agreement, Daiichi Sankyo and AgonOx will collaborate on preclinical development of the programme. Following preclinical assessment, Daiichi Sankyo has an exclusive option to research, develop, manufacture and commercialize the program worldwide. Financial terms of the agreement were not disclosed.
“We are excited to collaborate with AgonOx, which has extensive expertise in validating the expression and function of immuno-oncology targets,” said Antoine Yver, MD, MSc, executive vice president and global head, oncology research and development, Daiichi Sankyo. “While this collaboration will help strengthen our immuno-oncology capabilities, it also aligns with our overall mission of discovering and delivering science that can change the standard of care for patients with cancer.”
Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address diversified, unmet medical needs of patients in both mature and emerging markets.
AgonOx is a privately held biotechnology company developing a pipeline of novel immunotherapy drugs targeting key regulators of the immune response to cancer.
